Nimorazol
|
|
|
- CAS-Nr.
- 6506-37-2
- Bezeichnung:
- Nimorazol
- Englisch Name:
- Nimorazole
- Synonyma:
- K-1900;Esclama;Acterol;Naxogin;Nulogyl;Nimorazol;NIMORAZOLE;Acterol forte;Nitrimidazine;Nimorazole, >=98%
- CBNumber:
- CB1839955
- Summenformel:
- C9H14N4O3
- Molgewicht:
- 226.23
- MOL-Datei:
- 6506-37-2.mol
|
Nimorazol Eigenschaften
- Schmelzpunkt:
- 110-111°
- Siedepunkt:
- 367.84°C (rough estimate)
- Dichte
- 1.2673 (rough estimate)
- Brechungsindex
- 1.6300 (estimate)
- storage temp.
- 2-8°C
- Löslichkeit
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 6.65±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Off-White to Yellow
- CAS Datenbank
- 6506-37-2
- NIST chemische Informationen
- Nimorazole(6506-37-2)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| HS Code |
2934999090 |
|
|
| Toxizität |
LD50 orally in mice: 1530 mg/kg (Cavalleri) |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H340 |
Kann genetische Defekte verursachen. |
Keimzellmutagenität |
Kategorie 1B |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
Nimorazol Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Nimorazole is 5-nitroimidazole with antimicrobial and radiosensitizing activities. It is active against
T. vaginalis in a Coulter counter antimicrobial assay (EC
50 = 2.55 fmol/cell) and
G. intestinalis (IC
50 = 0.393 μM). Nimorazole reduces the number of vaginal trichomonads in a mouse model of
T. vaginalis intravaginal infection (ED
50 = 5.62 mg/kg). Under hypoxic conditions, nimorazole enhances radiation-induced SCC-7 tumor cell death
in vitro and
in vivo.
Verwenden
Nimorazole is an antimicrobial with activity against anaerobic bacteria and protozoa.
Pharmazeutische Anwendungen
An orally administered 5-nitroimidazole. It is slightly soluble in water at room temperature, soluble in alcohols, acetone and chloroform. The spectrum includes T. vaginalis, G. lamblia, E. histolytica, anaerobic bacteria and G. vaginalis. Activity against B. fragilis and Fusobacterium spp. is similar to or slightly less than that of metronidazole (mean MIC 0.25–1 mg/L).
A peak blood concentration of about 32 mg/L occurs within 2 h of a 500 mg oral dose. High concentrations are achieved in saliva and vaginal secretions. Excretion is principally via the urine where the drug appears as metabolites which display antimicrobial and antiprotozoal activity less than that of the parent drug.
It is generally well tolerated even at the high doses required in conjunction with radiotherapy for the treatment of head and neck tumors. Adverse effects are the same as those of metronidazole. Disulfiram-like reactions appear to be rare.
Clinical uses are similar to those of metronidazole. It is also used as a hypoxic radiosensitizer in the radiotherapy of head and neck tumors.
Nimorazol Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Nimorazol Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 117)Lieferanten
6506-37-2(Nimorazol)Verwandte Suche:
- Nimorazole 4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine
- Nimorazole, 6506-37-2
- 1-(2-N-Morpholinylethyl)-5-nitroimidazole
- Acterol
- Acterol forte
- Esclama
- Morpholine, 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]-
- Morpholine, 4-[2-(5-nitroimidazol-1-yl)ethyl]-
- 4-(2-NITROIMIDAZOL-1-YL)ETHYL)MORPHOLINE
- Nimorazole, >=98%
- NIMORAZOLE
- 4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine
- 4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine
- K-1900
- Naxogin
- Nitrimidazine
- Nulogyl
- 1-(.beta.-Morpholinoethyl)-5-nitroimidazole
- 1-( -Morpholinoethyl)-5-nitroimidazole
- NITRIMIDAZINE; NAXOGIN
- Nimorazol
- Nimorazole USP/EP/BP
- 6506-37-2
- 6505-37-2
- Inhibitors
- API
